Evidence map›Paper›PMID 34406515›Full record

ArticleEJNMMI physics2021

Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis.

George Sgouros, Bin He, Nitya Ray, Dale L Ludwig, Eric C Frey

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Pharmaceutics · 2023
    Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

George SgourosRussell H. Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, CRB II 4M.61, 1550 Orleans St., Baltimore, MD, 21287, USA. gsgouros@jhmi.edu.ORCID http://orcid.org/0000-0002-1328-7114
Bin HeRadiopharmaceutical Imaging and Dosimetry, LLC (Rapid), Baltimore, MD, USA.
Nitya RayActinium Pharmaceuticals, Inc., New York, NY, USA.
Dale L LudwigActinium Pharmaceuticals, Inc., New York, NY, USA.
Eric C FreyRadiopharmaceutical Imaging and Dosimetry, LLC (Rapid), Baltimore, MD, USA.
Actinium Pharmaceuticals (United States) · USJohns Hopkins University · US

Funding

Dose-Response in Radionuclide TherapyR01CA116477 · NCI · JOHNS HOPKINS UNIVERSITY · PI HOBBS, ROBERT FRANCOIS, SGOUROS, GEORGE · 2006 to 2022
$7.1M
Combined Biologic and Radiopharmaceutical Therapy of Breast CancerR01CA187037 · NCI · JOHNS HOPKINS UNIVERSITY · PI SGOUROS, GEORGE · 2015 to 2019
$2.4M
NCI NIH HHS R01CA116477NCI NIH HHS R01 CA187037NCI NIH HHS R01CA187037
6 · The paper itself

Abstract

backgroundActinium-225 is an alpha-particle emitter under investigation for use in radiopharmaceutical therapy. To address limited supply, accelerator-produced

resultsBased on our modeling, the tissue specific absorbed dose from

conclusionsThese results suggest that the absorbed dose arising from

Indexed as

Actinium-225Alpha-emitterCompartmental modelingDosimetryRadiopharmaceutical therapy

Identifiers

PMID34406515
PMCPMC8374020
OpenAlexW3196268644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.